The "Halftime Report" traders give their trades for the second half.» Read More
*Mylan jumps after offering to buy Perrigo for about $29 bln. *Alcoa flat in extended trading after results. NEW YORK, April 8- U.S. stocks ended a volatile session with modest gains on Wednesday after minutes from a U.S.
*Fed minutes indicate rate hike in 2015, but members differ on month. *Mylan jumps after offering to buy Perrigo for about $29 bln. NEW YORK, April 8- U.S. stocks rose on Wednesday, but trading was volatile following the release of minutes from the U.S.
*Mylan jumps after offering to buy Perrigo for about $29 bln. Mylan shares jumped 14.4 percent to $68.15, boosting the Nasdaq and the S&P healthcare sector, on news it offered to buy Perrigo for about $29 billion in cash and stock. Perrigo shares jumped 21.7 percent to $200.50.
DUBLIN, Feb 26- Malin, an Irish company set up by a number of former Elan executives to invest in privately held life science assets, said it plans to raise between 275 million and 325 million euros in one of Europe's biggest biotechnology IPOs. Former Elan chief executive Kelly Martin and chairman Bob Ingram, who sold the Irish stock market stalwart to Perrigo for...
NEW YORK, Nov 12- Mathew Martoma, a former portfolio manager at billionaire Steven A. Cohen's SAC Capital Advisors LP hedge fund, on Wednesday lost a bid to stay out of prison while he appeals his insider trading conviction. The 2nd U.S. Circuit Court of Appeals in New York lifted a stay that had enabled Martoma to avoid beginning a nine-year prison sentence for...
NEW YORK, Nov 4- Mathew Martoma, a former portfolio manager at billionaire Steven A. Cohen's SAC Capital Advisors LP hedge fund, won an order Tuesday to delay the date he would begin serving a nine-year prison term for insider trading. The 2nd U.S. Circuit Court of Appeals in New York agreed to delay Martoma's surrender date past Nov. 10 until after an appellate panel...
NEW YORK, Oct 30- The U.S. Securities and Exchange Commission wants to make its $602 million settlement with SAC Capital Advisors hedge fund available to people who say they are victims of illicit trading by a former SAC portfolio manager, according to a lawyer representing them. District Judge Victor Marrero, who is presiding over the SEC's case, must still...
The stock market might be making new all-time highs on almost a daily basis, but that doesn’t mean there isn’t bargain to be had.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
U.S. health officials finalized guidelines for infant formula makers that aim to ensure products meet certain quality controls to keep them safe.
Some of Wednesday's midday movers:
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
A couple of stocks stand to gain over the next two weeks, Paul Hickey of Bespoke Investment Group says.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.
Cramer believes there’s always opportunity in the market. You simply have to know where to look.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.
Jim Cramer has been a fan of this company for quite some time. But a good stock always needs new catalysts.